See our Coronavirus Product Pipeline
The Native Antigen Company is developing an extensive range of antigens and antibodies for the human coronaviruses, including SARS-CoV-2 (COVID-19).
The Native Antigen Company has been acquired by LGC
The Native Antigen Company has been acquired by LGC and is now a part of its Clinical Diagnostics Division. For more information, please click the button below.
See our Range of Coronavirus Antigens, Antibodies and Receptors
The Native Antigen Company offers an extensive range of antigens, antibodies and cell-surface receptors for various coronaviruses, including SARS-CoV-2 (COVID-19).
About The Native Antigen Company
The Native Antigen Company specialises in the development and manufacture of native and recombinant viral and bacterial antigens, antibodies and immunoassays, as well as bespoke product development and custom manufacturing. The company has decades of experience in producing high-quality proteins with its proprietary mammalian cell expression system to ensure correct glycosylation and proper folding. The Native Antigen Company’s high-quality reagents are widely adopted by leading pharmaceutical, in vitro diagnostic assay manufacturers, and academic groups in cutting-edge vaccine research and serology, where correct folding and glycosylation are vital.